Pure Global
NCT06405321

Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma

Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study in Guangxi, China (GUIDANCE)
Guangxi Medical University·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatocellular Carcinoma
Drug/Device/Intervention
Conversion or neoadjuvant therapy.
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Guangxi Medical University
Location
Nanning, China
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2019
End date
Dec 31, 2024
Enrollment
2000 participants
Primary outcome

Overall survival

Summary

This multicenter retrospective study which included patients with hepatocellular carcinoma
 (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options
 and the best benefit group.

ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06405321
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06405321 through Pure Global AI's free database. This phase not specified trial is sponsored by Guangxi Medical University and is currently Recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 2000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.